Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 9.88%
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 0.93 times
2
Flat results in Jun 25
3
With ROE of 9.46%, it has a Very Expensive valuation with a 4.50 Price to Book Value
4
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.99%
0%
-5.99%
6 Months
-11.76%
0%
-11.76%
1 Year
-6.09%
0%
-6.09%
2 Years
57.33%
0%
57.33%
3 Years
11.09%
0%
11.09%
4 Years
-31.6%
0%
-31.6%
5 Years
-6.57%
0%
-6.57%
Lonza Group AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.34%
EBIT Growth (5y)
1.42%
EBIT to Interest (avg)
15.72
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.47
Tax Ratio
15.50%
Dividend Payout Ratio
44.76%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
10.88%
ROE (avg)
9.88%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
4.50
EV to EBIT
38.75
EV to EBITDA
23.38
EV to Capital Employed
3.45
EV to Sales
6.00
PEG Ratio
NA
Dividend Yield
0.77%
ROCE (Latest)
8.91%
ROE (Latest)
9.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 9 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
6,717.00
6,223.00
7.94%
Operating Profit (PBDIT) excl Other Income
1,980.00
1,945.00
1.80%
Interest
59.00
73.00
-19.18%
Exceptional Items
-479.00
-53.00
-803.77%
Consolidate Net Profit
655.00
1,218.00
-46.22%
Operating Profit Margin (Excl OI)
202.30%
216.80%
-1.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 7.94% vs 15.05% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -46.22% vs 79.91% in Dec 2022
About Lonza Group AG 
Lonza Group AG
Pharmaceuticals & Biotechnology
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Company Coordinates 
Company Details
Muenchensteinerstrasse 38 , BASEL None : 4002
Registrar Details






